By using a patented chemotherapeutic galvanostat/potentiostat (CGP) like: The Joey™ from Innovative Potential™, drug molecules work better™ by affording: high-presicion surgical control, expanded reactivity and application options, and increased placement control over pharmaceutical concentration.

​

Work better™ is to have external control over bioactivation and to have improved efficacy versus the precursor compound.

​

Back in 2011 I demonstrated the practical application of electrochemical prodrug activation in the first proof-of-concept for EAC (figure1).

​

​

​

​

​

​

​

​

Figure 1. Cytotoxitity of the electrolysis of nontoxic prodrugs​ into cytotoxic molecules**. Left panel: cyclophosphamide; right panel: acetaminophen. Electrolysis was performed in a divided flow cell at three concentrations (0, 1, and 5 mM), and measured at three time points (0, 15, and 30 min), with a graphite anode. Viability is measured against EMT-6 cells using NADPH-flourescence assay and visual inspection following exclusion dye assay after 24 h treatment incubation. *: Student's t-test: 95% significant difference. **: Experimental data from Boudreau J. 2012. Electrochemical Generation of Reactive Toxicants and their application as chemotherapeutics. Thesis defense presentation. Pg. 22-23. University of Guelph.​

​

The toxicological principle that Figure 1 demonstrates is that: the cancer cells are not able to metabolize the prodrugs. Even if the concentration of prodrug is increased five-fold: there is no toxicity without electrolysis.

 

When you demonstrate that one of the longest and most widely used anti-cancer drugs: cyclophosphamide, is essentially nontoxic to cancer cells at millimolar concentrations (x0.001) after a 24 hour exposure, it becomes a different story.

​​

The Publications Page has more light-bulb toxicity demonstrations like this, but that's the point: the EAC technology is not just one drug, it is more! 

​​

An ideal EAC molecule is:

• bioactivatable; and,

• a non-toxic prodrug; and,

• only activated by a CGP, like The Joey™; and,

• short-lived but stable enough to be financially valuable; and,

• able to be be stored in fluctuating environmental conditions for a long period of time; and,

• already has a known biological profile; and,

• already has regulatory approvals; and,

• already has a large manufacturing base.

​​​​These qualities make EAC development ideal for cancer treatments, antibiotics, rural markets, pesticides, harsh environments, explosives, and space travel.

By sourcing the drug activation mechanism of actual biological enzymes the EAC process and the patented CGP devices act as artificial enzyme themselves!